Meratin Combi vaginal tablets, No. 10 in a blister pack with applicator, No. 10

In stock: 3
$80.00

Ingredients

Active ingredients: ornidazole, neomycin sulfate, nystatin, prednisolone;

1 tablet contains: ornidazole 500 mg, neomycin sulfate 100 mg, nystatin 100,000 IU, prednisolone 3 mg;

Excipients: corn starch, microcrystalline cellulose, propyl gallate, sodium methylparaben (E 219), sodium propylparaben (E 217), anhydrous colloidal silicon dioxide, talc, magnesium stearate, sodium starch glycolate (type A), sodium carmellose.

Dosage Form

Vaginal tablets.

Main physical and chemical properties: cream-colored, cartridge-shaped, biconvex, uncoated tablets, embossed with “MERATIN COMBI” on one side. The presence of small dark spots and marbling is permitted.

Pharmacotherapeutic group

Antimicrobial and antiseptic agents used in gynecology. Imidazole derivatives and corticosteroids. ATX code G01B F.

Pharmacological Properties

Pharmacodynamics.

Ornidazole. The mechanism of action of ornidazole involves disruption of the DNA structure in microorganisms sensitive to it. The drug easily penetrates the microbial cell and, by binding to DNA, disrupts the replication process. Ornidazole is active against Trichomonas vaginalis, Entamoeba histolytica, Giardia intestinalis, as well as certain anaerobic bacteria, such as Bacteroides and Clostridium spp., Fusobacterium spp., and anaerobic cocci.

Neomycin is an antibiotic belonging to the aminoglycoside group. Aminoglycosides are highly active against both Gram-negative and Gram-positive bacteria. Nystatin is an antifungal drug belonging to the polyene group. Nystatin acts on the fungal cell membrane by binding to one of its components—ergosterol. As a result, the structure of the fungal cell is disrupted, and it dies. This component of the drug exhibits selective toxicity toward fungi, since human and bacterial cells contain cholesterol instead of ergosterol.

Prednisolone is a synthetic corticosteroid used to reduce inflammation. Prednisolone inhibits the secretion and release of inflammatory mediators. Prednisolone suppresses proliferative processes in inflammatory diseases and reduces the likelihood of scar formation.

Pharmacokinetics.

When applied topically, the concentration of the drug in vaginal tissues significantly exceeds the concentration achieved with oral or intravenous administration.

Indications

Meratin Combi is indicated:

  • for the treatment of gynecological conditions such as bacterial vaginosis and vaginitis, trichomoniasis, and fungal vaginitis caused by Candida albicans; vaginitis caused by mixed infections (Trichomonas, anaerobic flora, including Gardnerella and yeast-like fungi);
  • for prophylactic purposes prior to surgical treatment of gynecological conditions, for vaginal sanitation prior to childbirth or abortion, before and after the insertion of intrauterine contraceptives, before and after diathermocoagulation of cervical erosions, and before an intrauterine examination.

Contraindications

Hypersensitivity to any of the drug’s components or to other imidazole derivatives. Systemic and local infectious diseases prior to the initiation of specific therapy.

Interactions with Other Medications and Other Forms of Interaction

Interactions related to prednisolone

Undesirable combinations:

  • with acetylsalicylic acid: increased risk of bleeding when used concomitantly with an anti-inflammatory dose of acetylsalicylic acid (≥ 1 g per dose or ≥ 3 g per day).

Combinations requiring caution:

  • with anticonvulsants and enzyme inducers: decreased plasma concentrations and reduced efficacy of corticosteroids due to increased hepatic metabolism. The consequences of this are particularly severe (or significant) for patients with Addison’s disease receiving hydrocortisone therapy, as well as in cases of organ transplantation. Monitoring of clinical and laboratory parameters is necessary, as is dose adjustment of corticosteroids during therapy and after discontinuation of enzyme-inducing agents;
  • with isoniazid: a decrease in plasma isoniazid concentrations due to increased hepatic metabolism of isoniazid and decreased hepatic metabolism of glucocorticosteroids;
  • with rifampicin: a decrease in plasma concentrations and efficacy of corticosteroids due to increased hepatic metabolism following interaction with rifampicin. The consequences of this are particularly severe (or significant) for patients with Addison’s disease receiving hydrocortisone therapy, as well as in cases of organ transplantation. Clinical and laboratory parameters should be monitored, and the dose of corticosteroids should be adjusted during therapy and after discontinuation of rifampicin treatment;
  • With other hypokalemic medications: increased risk of hypokalemia. Serum potassium levels should be monitored and adjusted as necessary;
  • With digitalis preparations: hypokalemia exacerbates the toxic effects of digitalis preparations. Before treatment with this drug, assess for hypokalemia, determine serum potassium levels, and perform an electrocardiogram;
  • With drugs that cause “pirouette”-type polymorphic ventricular tachycardia: increased risk of developing ventricular arrhythmias, including “pirouette”-type polymorphic ventricular tachycardia. Before treatment with this drug, assess for hypokalemia, determine serum potassium levels, and perform an electrocardiogram;
  • with cyclosporine: potentiation of the effects of prednisolone, including Cushing-like states, and decreased carbohydrate tolerance (decreased prednisolone clearance);
  • with acetylsalicylic acid: increased risk of bleeding when taking antipyretic or analgesic doses of ≥ 500 mg per dose or < 3 g per day;
  • when taken with nonsteroidal anti-inflammatory drugs (NSAIDs): increased risk of peptic ulcer disease and gastrointestinal bleeding;
  • with fluoroquinolones: increased risk of tendinitis or tendon rupture (rare), especially in patients receiving long-term corticosteroid therapy.

Special Considerations

This medication should be used with caution and under constant medical supervision in patients who are concurrently taking systemic corticosteroids, or who have osteoporosis, hypertension, heart failure, severe emotional disorders (including a history thereof), tuberculosis, diabetes mellitus, glaucoma, corticosteroid-induced myopathy, hepatic insufficiency, epilepsy, peptic ulcer disease, hypothyroidism, recent myocardial infarction.

The drug should be used with caution in patients with severe pseudoparalytic myasthenia gravis, nonspecific colitis, diverticulitis, and recent intestinal anastomoses.

Despite the drug’s topical application, systemic absorption is possible, especially in cases of vaginal inflammation.

Adverse reactions can be minimized by using the drug for the shortest possible treatment period and under constant medical supervision.

Meratin Combi may damage latex contraceptives and reduce the effectiveness of topical contraceptives; therefore, during treatment with this medication, patients should refrain from sexual intercourse and avoid using local contraceptives (contraceptive caps, latex condoms, spermicides).

Patients should use separate personal hygiene items (washcloth, towel, etc.), wear natural cotton underwear, and use panty liners instead of tampons.

The sexual partner must be treated at the same time to prevent reinfection.

Sodium methylparaben (E 219) and sodium propylparaben (E 217), which are components of the medication, may cause allergic reactions (possibly delayed).

Pregnancy and lactation.

It is contraindicated during the first trimester of pregnancy. Use during the second and third trimesters is possible if the expected benefit to the mother outweighs the potential risk to the fetus, since the concentration of the drug’s components in the systemic circulation is minimal due to low absorption. The drug may be used during breastfeeding. If the drug is used as part of combination therapy with the oral form of ornidazole, breastfeeding should be discontinued.

It does not affect the ability to operate vehicles or machinery.

It has no effect.

Dosage and Administration

Insert 1 tablet deep into the vagina at night. After insertion, the patient should lie down for at least 15 minutes. The average duration of treatment is 10 days.

Administration instructions: 1. Place the vaginal tablet into the applicator.

  1. Immerse the applicator with the tablet in warm (30–40 °C) boiled water or saline solution (for people prone to allergic reactions) for 15–30 seconds.
  2. Gently insert the applicator with the tablet as deeply as possible into the vagina (preferably while lying on your back).
  3. Leave the tablet in the vagina after removing it from the applicator; then remove the applicator.

Practical Tips.

For hygienic insertion of the tablet, use a new applicator for each use.

Treatment should be accompanied by good personal hygiene: wear cotton underwear, avoid douching, use panty liners instead of tampons during treatment, and use specific personal hygiene items (a washcloth, towel, etc.).

Do not interrupt the course of treatment during menstruation.

Children.

Meratin Combi is not indicated for use in children.

Overdose

Due to the drug’s local action, no cases of overdose have been observed. Side effects may be more pronounced.

Treatment is symptomatic.

Side Effects

Immune system: hypersensitivity.

Skin and subcutaneous tissue disorders: allergic dermatitis, rash, itching, hives.

Reproductive system: reactions at the application site such as tingling or irritation, erosion, vaginal edema, vaginal burning, vulvovaginal erythema, vulvovaginal pain, vulvovaginal itching. If systemic effects of corticosteroids occur, delayed healing of wounds and fissures, as well as mucosal atrophy, may result.

If side effects occur, discontinue use of the medication and consult a doctor.

Shelf life

2 years.

Storage Conditions

Store at a temperature not exceeding 25 °C in the original packaging and out of the reach of children.

Packaging

10 tablets per blister pack. 1 blister pack containing 10 applicators in a cardboard box.